Candel Therapeutics Inc. (NASDAQ: CADL) entered into a commercialization agreement with EVERSANA to support the potential U.S. launch of aglatimagene besadenovec for treating intermediate- to high-risk, localized prostate cancer.

Under the agreement, EVERSANA will provide integrated commercialization services including data and analytics, medical affairs, market access and field operations. The partnership positions Candel for a potential commercial launch following a planned Biologics License Application submission in Q4 2026.

EVERSANA joins IDEA Pharma, which has been providing market strategies and positioning for the drug candidate. Candel has been working with both organizations on pre-commercial activities since announcing the collaboration during its virtual Research and Development Day in December 2025.

"From the beginning, we designed Candel's commercial strategy around a partner-led model that allows us to stay focused on advancing the science and navigating the regulatory pathway," said Paul Peter Tak, President and Chief Executive Officer of Candel.

Aglatimagene is an investigational adenovirus-based immunotherapy designed to deliver the herpes simplex virus thymidine kinase gene to tumors. After administration with prodrug valacyclovir, it aims to trigger immunogenic cell death and promote anti-tumor immune responses.

The drug has received Fast Track Designation and Regenerative Medicine Advanced Therapy Designation from the FDA for newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease. More than 1,000 patients have been dosed with aglatimagene in clinical trials.

Candel recently completed a pivotal phase 3 clinical trial of aglatimagene in localized prostate cancer under a Special Protocol Assessment agreed with the FDA. The company also completed phase 2a trials in non-small cell lung cancer and pancreatic ductal adenocarcinoma.